Coronary Artery Disease
Conditions
Brief summary
This study aims at evaluating the feasibility of CT myocardial perfusion imaging in daily clinical practice and compare it to SPECT perfusion imaging in order to assess sensitivity and specifity of CT myocardial perfusion imaging compared to SPECT.
Detailed description
If after the clinically indicated CCTA a myocardial perfusion examination is indicated, first a single ultra low dose CT scan will be performed to look for late enhancement of potentially scarred myocardium. Together with the contrast agent co-injection of the clinically indicated tracer 99mTc-Tetrofosmin will be performed for later scintigraphic perfusion evaluation. After stress perfusion imaging CT rest perfusion imaging will be performed in a similar fashion. After acquisition of CT rest perfusion images scintigraphic stress and rest image acquisition will be performed as in daily clinical routine with an additional administration of 99mTc-Tetrofosmin resting dose if necessary. CT stress and rest perfusion will be compared to the clinically indicated and well established SPECT examination.
Interventions
OTHERCT-MPI and SPECT-MPI
All patients undergo CT-MPI plus SPECT-MPI
Sponsors
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Referral for cardiac hybrid imaging with CCTA and SPECT * Male and Female subjects 18 years of age or older, * Written informed consent by the participant after information about the project
Exclusion criteria
* Contraindications for CCTA (including renal failure with a GFR \<60ml/min/1.73m2, allergies to ionidated constrast agents) * Inability to follow the examination procedure due to language barriers, mental disease, dementia etc. * Pregnancy or breast feeding * Known allergies to iodinated contrast agent (Visipaque ®), 99mTc-Tetrofosmin (Myoview ®), betablockers (Beloc i.v. ®) or nitrates (Isoket -Spray®) * Hypersensitivity to adenosine * Asthma bronchiale
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validation of CT-MPI against SPECT-MPI | 2 years | Sensitivity and specificity of CT-MPI to diagnose obstructive coronary artery disease using SPECTR-MPI as the standard reference |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Parameters influencing image quality of CT-MPI - Body physique | 2 years | Correlation between visually assessed image quality of CT-MPI and patient's body mass index |
| Parameters influencing image quality of CT-MPI - Heart rate | 2 years | Correlation between visually assessed image quality of CT-MPI and patient's heart rate during the scan |
Countries
Switzerland
Outcome results
None listed